Morgan Stanley’s PureTech Health PRTC Stock Holding History

Morgan Stanley’s Portfolio PRTC Stock Details PRTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-100	Closed	-$1.98K	–	8233
2025 Q1	$1.98K	Hold	100	–	–	﹤0.01%	7181
2024 Q4	$1.85K	Hold	100	–	–	﹤0.01%	7211
2024 Q3	$2.06K	Sell	100 -2,727	-96%	-$59.6K	﹤0.01%	7130
2024 Q2	$70.7K	Buy	+2,827	New	+$79.2K	﹤0.01%	6079

Other funds holding PRTC

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.23B AUM 15.55% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return

PAP

Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return

AUB

Atlantic Union Bankshares Glen Allen, Virginia $5.21B AUM 19.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley's PRTC Position: Q2 2025 in Review

Morgan Stanley sold out of PureTech Health (PRTC) in Q2 2025, closing a stake of 100 shares — an estimated $1.98K sold.

Morgan Stanley first reported a position in PRTC in Q2 2024 and held it in 4 quarters. The position peaked at $70.7K in Q2 2024. 8 funds tracked by Wall St. Rank hold PRTC as of Q2 2025.

Morgan Stanley reported no remaining PureTech Health position as of Q2 2025 after selling out during the quarter.
Morgan Stanley sold 100 PureTech Health shares in Q2 2025, an estimated $1.98K.
Morgan Stanley first reported a position in PureTech Health in Q2 2024 and held it in 4 quarters.
Morgan Stanley's PureTech Health position peaked at $70.7K in Q2 2024.
8 funds tracked by Wall St. Rank held PureTech Health as of Q2 2025.

Based on Morgan Stanley's 13F filing for Q2 2025, filed 15 Aug 2025.